Financial Contrast: ConforMIS (CFMS) vs. Its Rivals
ConforMIS (NASDAQ: CFMS) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it contrast to its peers? We will compare ConforMIS to related companies based on the strength of its valuation, profitability, analyst recommendations, dividends, risk, institutional ownership and earnings.
Valuation & Earnings
This table compares ConforMIS and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|ConforMIS||$79.90 million||-$57.58 million||-1.98|
|ConforMIS Competitors||$1.67 billion||$207.58 million||85.41|
ConforMIS’s peers have higher revenue and earnings than ConforMIS. ConforMIS is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
ConforMIS has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, ConforMIS’s peers have a beta of 0.47, suggesting that their average stock price is 53% less volatile than the S&P 500.
This is a summary of current ratings and target prices for ConforMIS and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ConforMIS currently has a consensus price target of $6.13, indicating a potential upside of 131.13%. As a group, “Medical Devices & Implants” companies have a potential upside of 36.86%. Given ConforMIS’s higher possible upside, analysts clearly believe ConforMIS is more favorable than its peers.
Institutional & Insider Ownership
36.1% of ConforMIS shares are owned by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 9.6% of ConforMIS shares are owned by insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares ConforMIS and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
ConforMIS peers beat ConforMIS on 8 of the 12 factors compared.
ConforMIS Company Profile
ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints. It offers a line of customized knee implants designed to restore the natural shape of a patient’s knee. It offers iTotal CR, which is a total knee replacement implant. Its iFit technology platform consists of three elements, including iFit Design, its algorithms and computer software that is used to design customized implants and associated single-use patient-specific instrumentation referred to as iJigs, based on computed tomography scans of the patient and to prepare a surgical plan customized for the patient (iView); iFit Printing, which is a three-dimensional printing technology used to manufacture iJigs, and iFit Just-in-Time manufacturing and delivery capabilities.
Receive News & Ratings for ConforMIS Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.